Evidence map›Paper›PMID 35192418›Full record

ArticleScience signaling2022

Piquing our interest: Insights into the role of PEAK3 in signaling and disease.

Michael D Paul, Hayarpi Torosyan, Natalia Jura

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Science signaling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael D PaulCardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-8479-110X
Hayarpi TorosyanCardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94158, USA.
Natalia JuraCardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-5129-641X
University of California, San Francisco · US

Funding

Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY, KROGAN, NEVAN J · 2017 to 2021
$10.9M
STRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008284 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORTEMME, TANJA · 1988 to 2022
$10.1M
Structural and Functional Studies of HER ReceptorsR35GM139636 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Natalia Jura · 2021 to 2026
$2.5M
The structural and functional basis of MET exon 14 activation and acquired drug resistanceR01CA230263 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC, JURA, NATALIA · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA230263NCI NIH HHS U54 CA209891NIGMS NIH HHS R35 GM139636NIGMS NIH HHS T32 GM008284
6 · The paper itself

Abstract

Pseudokinases are critical signaling hubs that are increasingly appreciated as important disease targets. In this issue of

Indexed as

Signal Transduction

Identifiers

PMID35192418
PMCPMC9288111
OpenAlexW4213442795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.